{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:28:17Z","timestamp":1770888497851,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10147-021-01988-8","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T07:02:56Z","timestamp":1627369376000},"page":"2104-2112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-9128","authenticated-orcid":false,"given":"Kota","family":"Iida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-7356","authenticated-orcid":false,"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motokiyo","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eijiro","family":"Okajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Sazuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotaka","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yasumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikiya","family":"Taoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"1988_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/iju.12749","volume":"22","author":"M Miyake","year":"2015","unstructured":"Miyake M, Gotoh D, Shimada K et al (2015) Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: long-term follow-up experience at a single institute. Int J Urol 22:541\u2013547","journal-title":"Int J Urol"},{"key":"1988_CR2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/iju.14281","volume":"27","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Shiraishi K, Azuma H et al (2020) Clinical practice guidelines for bladder cancer 2019 update by the Japanese Urological Association: summary of the revision. Int J Urol 27:702\u2013709","journal-title":"Int J Urol"},{"key":"1988_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM et al (2019) European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update. Eur Urol 76:639\u2013657","journal-title":"Eur Urol"},{"key":"1988_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol 198:552\u2013559","journal-title":"J Urol"},{"key":"1988_CR5","doi-asserted-by":"publisher","first-page":"E216","DOI":"10.1111\/j.1464-410X.2011.10894.x","volume":"110","author":"H Shirakawa","year":"2012","unstructured":"Shirakawa H, Kikuchi E, Tanaka N et al (2012) Prognostic significance of Bacillus Calmette-Guerin failure classification in non-muscle-invasive bladder cancer. BJU Int 110:E216\u2013E221","journal-title":"BJU Int"},{"key":"1988_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/BLC-159001","volume":"1","author":"SP Lerner","year":"2015","unstructured":"Lerner SP, Dinney C, Kamat A et al (2015) Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer 1:29\u201330","journal-title":"Bladder Cancer"},{"key":"1988_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3233\/BLC-150039","volume":"2","author":"RL Steinberg","year":"2016","unstructured":"Steinberg RL, Thomas LJ, Mott SL et al (2016) Bacillus Calmette-Gu\u00e9rin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease. Bladder Cancer 2:215\u2013224","journal-title":"Bladder Cancer"},{"key":"1988_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","volume":"74","author":"Z Klaassen","year":"2018","unstructured":"Klaassen Z, Kamat AM, Kassouf W et al (2018) Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations. Eur Urol 74:597\u2013608","journal-title":"Eur Urol"},{"key":"1988_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/iju.14153","volume":"27","author":"E Kikuchi","year":"2020","unstructured":"Kikuchi E, Hayakawa N, Fukumoto K et al (2020) Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: its definition and future therapeutic strategies. Int J Urol 27:108\u2013116","journal-title":"Int J Urol"},{"key":"1988_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"key":"1988_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124\u20131129","journal-title":"J Urol"},{"key":"1988_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/iju.14210","volume":"27","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Shiraishi K, Azuma H et al (2020) Clinical practice guidelines for bladder cancer 2019 edition by the Japanese Urological Association: revision working position paper. Int J Urol 27:362\u2013368","journal-title":"Int J Urol"},{"key":"1988_CR13","first-page":"252","volume":"3","author":"AM Kamat","year":"2019","unstructured":"Kamat AM, Gontero P, Palou J (2019) How should I manage a patient with tumor recurrence despite adequate Bacille Calmette-Guerin? Eur Urol 3:252\u2013257","journal-title":"Eur Urol"},{"key":"1988_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, Meijden APM, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466\u2013477","journal-title":"Eur Urol"},{"key":"1988_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/MOU.0000000000000086","volume":"24","author":"T Seisen","year":"2014","unstructured":"Seisen T, Comperat E, Leon P (2014) Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection. Curr Opin Urol 24:524\u2013531","journal-title":"Curr Opin Urol"},{"key":"1988_CR16","doi-asserted-by":"publisher","first-page":"21.e1","DOI":"10.1016\/j.urolonc.2014.10.013","volume":"33","author":"A Soave","year":"2015","unstructured":"Soave A, Schmidt S, Dahlem R et al (2015) Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? Urol Oncol 33:21.e1-21.e9","journal-title":"Urol Oncol"},{"key":"1988_CR17","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41598-017-01532-7","volume":"7","author":"BS Tae","year":"2017","unstructured":"Tae BS, Kim JK, Kang M et al (2017) Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patients. Sci Rep 7:1380","journal-title":"Sci Rep"},{"key":"1988_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/bju.13904","volume":"120","author":"ML Blute","year":"2017","unstructured":"Blute ML, Kucherov V, Rushmer TJ et al (2017) Reduced estimated glomerular filtration rate (eGFR<60 mL\/min\/1.73\u00a0m2) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int 120:387\u2013393","journal-title":"BJU Int"},{"key":"1988_CR19","first-page":"1659","volume":"24","author":"B Ucpinar","year":"2019","unstructured":"Ucpinar B, Erbin A, Ayranci A et al (2019) Prediction of recurrence in non-muscle invasive bladder cancer patients. Do patient characteristics matter? J BUON 24:1659\u20131665","journal-title":"J BUON"},{"key":"1988_CR20","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.urolonc.2014.05.009","volume":"32","author":"S Rausch","year":"2014","unstructured":"Rausch S, Hennenlotter J, Todenhofer T et al (2014) Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression-introducing a novel prognostic model for bladder cancer recurrence. Urol Oncol 32:1178\u20131183","journal-title":"Urol Oncol"},{"key":"1988_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cca.2010.12.030","volume":"11","author":"GA Roth","year":"2011","unstructured":"Roth GA, Eichinger DL, Ankersmit HJ et al (2011) Increased total cytokerain-18 serum and urine levels in chronic kidney disease. Clin Chim Acta 11:713\u2013717","journal-title":"Clin Chim Acta"},{"key":"1988_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11934-019-0952-y","volume":"20","author":"VT Packiam","year":"2019","unstructured":"Packiam VT, Werntz RP, Steinberg GD (2019) Current clinical trials in non-muscle-invasive bladder cancer: heightened need in an era of chronic BCG shortage. Curr Urol Rep 20:84","journal-title":"Curr Urol Rep"},{"key":"1988_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.urolonc.2017.12.020","volume":"36","author":"N Mukherjee","year":"2018","unstructured":"Mukherjee N, Svatek RS, Mansour AM (2018) Role of immunotherapy in Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer. Urol Oncol 36:103\u2013108","journal-title":"Urol Oncol"},{"key":"1988_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2217\/fon-2019-0817","volume":"16","author":"AM Kamat","year":"2020","unstructured":"Kamat AM, Shore N, Hahn N et al (2020) KEYNOTE-676: phase III study of BCG and pembrolizmab for persistent\/recurrent high-risk NMIBC. Future Oncol 16:507\u2013516","journal-title":"Future Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01988-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-01988-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01988-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T16:42:34Z","timestamp":1634488954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-01988-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1988"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-01988-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors disclose no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}